Study Links GLP-1 Medications to Lower Breast Cancer Risk in Women
A large retrospective study has found that women using GLP-1 medications, typically prescribed for type 2 diabetes and obesity, have a significantly lower risk of developing breast cancer. The study analyzed health records of nearly 112,000 women aged 45 to 80 with a BMI of 25 or higher, revealing that those on GLP-1s were up to 35% less likely to be diagnosed with breast cancer. The research suggests that weight loss and metabolic changes associated with GLP-1 use may contribute to this reduced risk. However, the study only shows an association, not causation, and further research is needed to understand the mechanisms behind this link. 
